Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZNF445 | CTRPv2 | pan-cancer | AAC | 0.27 | 6e-14 |
mRNA | FAM117B | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-13 |
mRNA | PBRM1 | CTRPv2 | pan-cancer | AAC | 0.26 | 6e-13 |
mRNA | NASP | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-12 |
mRNA | DOT1L | CTRPv2 | pan-cancer | AAC | 0.28 | 3e-12 |
mRNA | MYOF | CTRPv2 | pan-cancer | AAC | -0.26 | 5e-12 |
mRNA | PRR36 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-11 |
mRNA | KHDRBS1 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-11 |
mRNA | MEX3A | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-11 |
mRNA | HACE1 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-11 |